Indaptus Therapeutics, Inc. 8-K

What Happened
Indaptus Therapeutics, Inc. (INDP) filed an 8-K on Feb 27, 2026 reporting that at a Special Meeting stockholders approved amendments to the company’s charter. The amendments (1) increase the number of authorized shares of common stock to 1,000,000,000 and (2) permit stockholder action by written consent in lieu of a meeting. Stockholders also granted the Board authority to effect up to two reverse stock splits at a ratio within a 1-for-2 to 1-for-199 range, with the Board to determine the final ratio and timing.

Key Details

• Authorized common stock increased to 1,000,000,000 shares.
• Charter amended to allow stockholder approval by written consent (no meeting required if requisite holders sign).
• Board authorized to implement up to two reverse stock splits with an aggregate ratio within the range of 1-for-2 to 1-for-199; exact ratio and timing remain at the Board’s discretion.
• The company filed a Certificate of Amendment as part of this 8-K.

Why It Matters

• The increase in authorized shares gives Indaptus flexibility to issue additional shares or equity-linked awards for financing, acquisitions, or other corporate purposes, which can dilute existing holders if shares are issued.
• Allowing written consents can speed corporate actions without calling a full shareholder meeting.
• The reverse-split authority, if used, will reduce the number of outstanding shares and change per‑share metrics (shares outstanding, EPS, and stock price per share); it may also affect voting percentages and liquidity. The Board has not yet selected a split ratio or date—investors should watch for future filings disclosing those specifics.